Woo Young Sup, Park Joo Eon, Kim Do-Hoon, Sohn Inki, Hwang Tae-Yeon, Park Young-Min, Jon Duk-In, Jeong Jong-Hyun, Bahk Won-Myong
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation, Uiwang, Republic of Korea.
Psychiatry Investig. 2016 Jul;13(4):458-67. doi: 10.4306/pi.2016.13.4.458. Epub 2016 Jul 25.
The purpose of this study was to investigate the efficacy and tolerability of atypical antipsychotics (AAPs) with augmentation by blonanserin in schizophrenic patients.
aA total of 100 patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP were recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to their existing AAP regimen, which was maintained during the study period. Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 2, 4, 8, and 12. Predictors for PANSS response (≥20% reduction) were investigated.
The PANSS total score was significantly decreased at 12 weeks of blonanserin augmentation (-21.0±18.1, F=105.849, p<0.001). Moreover, 51.0% of participants experienced a response at week 12. Premature discontinuation of blonanserin occurred in 17 patients (17.0%); 4 of these patients dropped out due to adverse events. The patients who benefited the most from blonanserin were those with severe symptoms despite a treatment with a higher dose of AAP.
Blonanserin augmentation could be an effective strategy for patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP.
本研究旨在探讨在精神分裂症患者中，阿立哌唑联合布南色林强化治疗的疗效和耐受性。
在这项为期12周的开放标签、非对照、多中心研究中，共招募了100例对阿立哌唑治疗部分或完全无反应的精神分裂症患者。在研究期间维持其现有的阿立哌唑治疗方案，同时加用布南色林。主要在基线、第2周、第4周、第8周和第12周使用阳性和阴性症状量表（PANSS）评估疗效。研究PANSS反应（降低≥20%）的预测因素。
布南色林强化治疗12周时，PANSS总分显著降低（-21.0±18.1，F=105.849，p<0.001）。此外，51.0%的参与者在第12周出现反应。17例患者（17.0%）提前停用布南色林；其中4例患者因不良事件退出。尽管使用了高剂量的阿立哌唑进行治疗，但症状严重的患者从布南色林中获益最多。
对于对阿立哌唑治疗部分或完全无反应的精神分裂症患者，布南色林强化治疗可能是一种有效的策略。
